Table 2

Proptosis measurements for patients

Study phaseCaseBaseline study eyeWeek 24 study eyeBaseline fellow eyeWeek 24 fellow eyeBaseline asymmetryWeek 24 asymmetry
A: Teprotumumab group
 3127201717103
 322318181751
 3326202318.531.5
 242621222140
 252420201941
 262620232131
 272521221932
 282116151264
 292319181851
 2102221191635
 Mean24.219.619.5517.854.641.75
 SD1.921.582.662.632.061.81
B: Placebo group
 312828242444
 322119181831
 332020171832
 342526222333
 352121171843
 362424192054
 272421211932
 281617121641
 291921161734
 2102830252535
 2112525222332
 2122223181746
 Mean22.82319.319.83.53.1
 SD3.63.93.73.10.71.6